Âé¶¹ÒùÔº

June 5, 2017

Lactobacillus from yogurt inhibits multidrug-resistant bacterial pathogens

A Lactobacillus isolate from commercial yogurt, identified as Lactobacillus parafarraginis, inhibited the growth of several multidrug-resistant/extended spectrum β-lactamase bacteria from patients at a hospital in Washington, D.C.. The research was presented at ASM Microbe 2017 in New Orleans, Louisiana.

The inhibitory substance is a unique, bacteriocin-like peptide that is heat stable up to 121°C. Bacteriocins are produced by bacteria and released to kill other related bacteria that are not immune to their action.

"Considering the current upsurge of antibiotic resistance in hospitals, especially among the gram-negative , and the exigent need to find viable alternatives, findings from the study may hold promise for possible therapeutic application," said Rachelle Allen-McFarlane, doctoral candidate in the Biology Department at Howard University, Washington, D.C.

Lactobacillus parafarraginis KU495926, identified by 16S rRNA, was isolated from a sample of commercial yogurt on de Man-Rogosa-Sharpe agar by standard plate count technique under anaerobic conditions. The isolate exhibited the typical lactic acid bacterial characteristics: gram positive, catalase, oxidase, and motility negative. Screening of the antimicrobial activity by spot and well-diffusion assays showed that the isolate inhibited the growth of several multidrug-resistant/extended-spectrum β-lactamase gram-negative bacterial pathogens from a local .

Analyses of the extract by fast-perfusion liquid chromatography (FPLC), SDS-PAGE, and PCR () suggested that the inhibitory agent is a bacteriocin.

Load comments (0)

This article has been reviewed according to Science X's and . have highlighted the following attributes while ensuring the content's credibility:

Get Instant Summarized Text (GIST)

This summary was automatically generated using LLM.